ANVS - Annovis Bio, Inc. Stock Price and Quote

Index	-	P/E	-	EPS (ttm)	-3.57	Insider Own	30.74%	Shs Outstand	8.20M	Perf Week	-2.24%
Market Cap	111.68M	Forward P/E	-	EPS next Y	-3.50	Insider Trans	0.00%	Shs Float	5.31M	Perf Month	-11.78%
Income	-29.20M	PEG	-	EPS next Q	-1.14	Inst Own	9.10%	Short Float / Ratio	7.41% / 4.60	Perf Quarter	-22.85%
Sales	-	P/S	-	EPS this Y	-63.40%	Inst Trans	-3.85%	Short Interest	0.39M	Perf Half Y	1.16%
Book/sh	2.46	P/B	5.17	EPS next Y	23.70%	ROA	-89.40%	Target Price	46.00	Perf Year	29.32%
Cash/sh	1.91	P/C	6.65	EPS next 5Y	-	ROE	-102.70%	52W Range	8.98 - 23.91	Perf YTD	-2.46%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-45.21%	Beta	1.22
Dividend %	-	Quick Ratio	4.70	Sales past 5Y	-	Gross Margin	-	52W Low	45.88%	ATR	0.94
Employees	5	Current Ratio	4.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	42.86	Volatility	7.44% 6.51%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-85.20%	Profit Margin	-	Rel Volume	0.16	Prev Close	12.72
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Apr 03 BMO	Payout	-	Avg Volume	85.60K	Price	13.10
Recom	1.70	SMA20	-6.16%	SMA50	-12.23%	SMA200	-7.58%	Volume	7,849	Change	2.99%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-07-21	Reiterated	Maxim Group	Buy	$45 → $150

May-11-23 07:00AM	Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-04-23 09:55AM	Wall Street Analysts See a 213.78% Upside in Annovis Bio, Inc. (ANVS): Can the Stock Really Move This High? (Zacks)
Apr-27-23 07:00AM	Annovis Bio Announces Issuance of U.S. Patent Covering the Use of Lead Drug Candidate, Buntanetap, for Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis in Healthy or Sick Humans (GlobeNewswire)
Apr-25-23 11:36AM	Biogen (BIIB) Beats on Q1 Earnings, Ends Some Research Programs (Zacks)
Apr-21-23 10:00AM	Best Momentum Stocks to Buy for April 21st (Zacks) +7.55%
07:10AM	Loading…
07:10AM	New Strong Buy Stocks for April 21st (Zacks)
Apr-20-23 07:00AM	ANNOVIS BIO PROVIDES UPDATED WEBCAST LINK AND DIAL-IN INFORMATION FOR TODAY'S R&D WEBCAST (PR Newswire)
Apr-19-23 07:30AM	ANNOVIS BIO ANNOUNCES UPDATE ON RECRUITMENT INTO ITS PHASE 2/3 ALZHEIMER'S STUDY AND UPCOMING R&D WEBCAST (PR Newswire) -9.26%
Apr-18-23 10:00AM	Best Momentum Stocks to Buy for April 18th (Zacks)
09:55AM	Wall Street Analysts Think Annovis Bio, Inc. (ANVS) Could Surge 190.96%: Read This Before Placing a Bet (Zacks)
08:22AM	New Strong Buy Stocks for April 18th (Zacks)
Apr-13-23 07:30AM	ANNOVIS BIO TO HOLD LIVE WEBCAST TO REVIEW ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE CLINICAL PROGRAMS (PR Newswire) +8.40%
Apr-11-23 09:04AM	ANNOVIS BIO RAISES AGGREGATE GROSS PROCEEDS OF APPROXIMATELY $8.7 MILLION (PR Newswire) +18.29%
Apr-07-23 12:00PM	Annovis Bio, Inc. (ANVS) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Apr-06-23 06:36AM	We're Not Very Worried About Annovis Bio's (NYSE:ANVS) Cash Burn Rate (Simply Wall St.)
07:30AM	Loading…
Apr-03-23 07:30AM	ANNOVIS BIO ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE (PR Newswire) -21.54%
Mar-31-23 11:44AM	Avidity (RNA) Down on Update From Neuromuscular Disease Study (Zacks) -23.33%
Mar-30-23 08:50AM	Here's Why Momentum in Annovis Bio, Inc. (ANVS) Should Keep going (Zacks) -9.05%
Mar-29-23 12:27PM	Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up (Zacks) +12.76%
08:17AM	Bicycle (BCYC) up on Collaboration With Novartis for Conjugates (Zacks)
Mar-28-23 10:41AM	Vertex (VRTX) Inks Licensing Deal With CRISPR for Diabetes Drug (Zacks)
09:40AM	Are Medical Stocks Lagging Annovis Bio (ANVS) This Year? (Zacks)
Mar-27-23 12:09PM	Pharming (PHAR) Rare Disease Drug Joenja Gets FDA Nod, Stock Up (Zacks)
Mar-22-23 07:30AM	ANNOVIS BIO ANNOUNCES TWO PRESENTATIONS AT THE AD/PD 2023 INTERNATIONAL CONFERENCE ON ALZHEIMER'S AND PARKINSON'S DISEASES (PR Newswire)
Mar-21-23 11:24AM	COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar (Zacks)
Mar-15-23 11:52AM	Deciphera (DCPH) Gets Breakthrough Tag for Qinlock Expanded Use (Zacks)
09:05AM	Mirum's (MIRM) Livmarli Gets FDA Nod for Expanded Use, Stock Up (Zacks)
Mar-14-23 09:06AM	Seagen (SGEN) Set to be Acquired by Pfizer for $43 B, Stock Up (Zacks) +7.15%
Mar-13-23 10:19AM	Acadia (ACAD) Gets FDA Approval for Daybue for Rett Syndrome (Zacks) +5.03%
Mar-08-23 09:40AM	Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:59AM	Loading…
Feb-17-23 09:59AM	While insiders own 32% of Annovis Bio, Inc. (NYSE:ANVS), individual investors are its largest shareholders with 58% ownership (Simply Wall St.)
09:55AM	Wall Street Analysts Believe Annovis Bio, Inc. (ANVS) Could Rally 152.89%: Here's is How to Trade (Zacks)
09:40AM	Is Annovis Bio (ANVS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-10-23 01:36PM	Lab Notes: Center for Breakthrough Medicines expands offerings; Researchers identify key 'gene signature' (American City Business Journals)
Feb-08-23 07:30AM	Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease (PR Newswire)
Feb-01-23 09:55AM	Does Annovis Bio, Inc. (ANVS) Have the Potential to Rally 178.45% as Wall Street Analysts Expect? (Zacks) +9.26%
09:40AM	Are Medical Stocks Lagging McKesson (MCK) This Year? (Zacks)
07:30AM	Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses (PR Newswire)
Jan-25-23 07:30AM	ANNOVIS BIO ANNOUNCES PATIENT ENROLLMENT UPDATE FOR PHASE 3 STUDY OF BUNTANETAP FOR THE TREATMENT OF PARKINSON'S DISEASE (PR Newswire)
Jan-06-23 07:30AM	Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership Team (PR Newswire)
Dec-26-22 09:38AM	2022 in Review: After two years of IPOs, the region's publicly traded life sciences firms hit tough times (American City Business Journals)
Dec-02-22 09:55AM	Can Annovis Bio, Inc. (ANVS) Climb 251% to Reach the Level Wall Street Analysts Expect? (Zacks)
Nov-16-22 09:55AM	Wall Street Analysts Believe Annovis Bio, Inc. (ANVS) Could Rally 239%: Here's is How to Trade (Zacks) -5.39%
Nov-08-22 05:35PM	Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate Update (PR Newswire)
Oct-26-22 06:38AM	We're Not Very Worried About Annovis Bio's (NYSE:ANVS) Cash Burn Rate (Simply Wall St.)
Oct-20-22 07:30AM	Annovis Bio to Present at the 2022 ThinkEquity Investor Conference (PR Newswire)
Oct-11-22 07:30AM	Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease (PR Newswire)
Oct-07-22 12:57PM	Annovis (ANVS) Gains on FDA Authorization for AD Study (Zacks) -6.94%
Oct-06-22 09:24PM	Lab Notes: Venatorx lands federal contract that could be worth up to $318M; Annovis Bio receives FDA approval to proceed with trial (American City Business Journals)
07:30AM	Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease (PR Newswire)
Sep-29-22 07:30AM	Annovis Bio to Present at the 2022 Ladenburg Thalmann Healthcare Conference (PR Newswire)
Sep-13-22 07:30AM	Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases (PR Newswire)
Sep-10-22 09:55AM	Annovis Bio, Inc.'s (NYSE:ANVS) market cap up US$38m last week, benefiting both individual investors who own 59% as well as insiders (Simply Wall St.)
Sep-08-22 07:30AM	Annovis Bio's CEO Maria Maccecchini Issues Letter to Stockholders (PR Newswire) +15.65%
Aug-29-22 04:00PM	Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer (PR Newswire)
Aug-26-22 10:07AM	Lab Notes: Teleflex making acquisition valued at up to $300M; Vyant Bio files delayed quarterly report (American City Business Journals)
Aug-25-22 01:12PM	Annovis Bio (ANVS) Begins Dosing in Phase III Parkinson's Study (Zacks)
Aug-24-22 07:30AM	Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's Disease (PR Newswire) +5.88%
Aug-08-22 07:30AM	Annovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update (PR Newswire)
Aug-01-22 07:30AM	Annovis Bio to Participate on Alzheimer's Association International Conference Panel (PR Newswire)
Jul-14-22 07:30AM	Annovis Bio to Present at the Alzheimer's Association International Conference (PR Newswire)
Jul-07-22 10:17AM	FDA Gives Green Signal To Annovis Bio's Parkinson's Trial With Buntanetap (Benzinga) +13.12%
07:30AM	Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's Disease (PR Newswire)
Jun-28-22 06:30AM	Possible turnaround for Annovis Bio, Inc. (NYSE:ANVS) insiders, still down US$369k after a US$658k shopping spree (Simply Wall St.)
Jun-09-22 08:30AM	Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections (PR Newswire) -13.50%
May-05-22 08:55AM	We're Not Very Worried About Annovis Bio's (NYSE:ANVS) Cash Burn Rate (Simply Wall St.)
May-04-22 08:30AM	Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update (Newsfile) +14.06%
Apr-28-22 04:30PM	Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging (Newsfile)
Apr-26-22 07:15AM	Lantern Pharma's Board of Directors Names Maria Maccecchini, Ph.D. as a Director Nominee to Lantern's Board of Directors (PR Newswire) -9.58%
Apr-11-22 08:30AM	Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease (Newsfile)
Mar-23-22 08:30AM	Annovis Bio to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest (Newsfile)
Mar-21-22 01:16PM	Do Institutions Own Annovis Bio, Inc. (NYSE:ANVS) Shares? (Simply Wall St.)
Mar-18-22 08:30AM	Annovis Bio Presents at International Conference on Alzheimer's & Parkinson (AD/PD 2022) (Newsfile)
Mar-08-22 08:30AM	Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022 (Newsfile) +5.57%
Mar-03-22 08:30AM	Annovis Bio to Present at the Cowen 42nd Annual Health Care Conference (Newsfile) -6.57%
Jan-28-22 02:01PM	Lab Notes: AmerisourceBergen teams with UK tech firm; Chimeron Bio relocates to Center City (American City Business Journals)
Jan-25-22 12:14PM	FDA Guides Annovis Bio For Two Phase 3 Buntanetap Trial In Parkinson's Disease (Benzinga)
09:00AM	Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease (Newsfile)
Jan-19-22 04:42AM	As Annovis Bio, Inc.'s market cap (NYSE:ANVS) drops to US$117m, insiders might be questioning their decision to buy earlier this year (Simply Wall St.)
Jan-10-22 08:30AM	Annovis Bio Enhances Leadership Team with Two Senior Appointments (Newsfile)
Jan-07-22 12:29PM	Lab Notes: NRx seeks patent for Covid-19 therapy; Baudax Bio raises $4.2M (American City Business Journals)
Jan-05-22 08:30AM	Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401 (Newsfile) -9.07%
Jan-03-22 08:30AM	Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences (Newsfile) +12.51%
Dec-20-21 08:30AM	Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders (Newsfile)
Dec-14-21 08:29AM	Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics (Newsfile)
Nov-20-21 06:23AM	We're Hopeful That Annovis Bio (NYSE:ANVS) Will Use Its Cash Wisely (Simply Wall St.)
Nov-15-21 09:00AM	Annovis Bio Announces Transfer of Listing to the New York Stock Exchange (Newsfile) -7.06%
Nov-12-21 10:26AM	Annovis Bio Presented At The 14th Clinical Trials on Alzheimer's Disease Conference (Newsfile) -7.86%
Nov-09-21 08:30AM	Annovis Bio Presents Poster on Mechanism of Action at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference (Newsfile) -14.81%
Nov-03-21 10:43AM	SHAREHOLDER ALERT: Robbins LLP Investigates Annovis Bio, Inc. (ANVS) for Misleading Shareholders (Business Wire)
Nov-02-21 08:30AM	Annovis Bio to Present at the 14th Clinical Trials on Alzheimer's Disease (CTAD) Conference (Newsfile) +11.13%
Oct-18-21 08:10AM	DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Annovis Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (ACCESSWIRE)
07:00AM	Annovis Bio Stock Tumbled, and CEO Maria L. Maccecchini Bought Shares (Barrons.com)
Oct-15-21 09:00PM	ANNOVIS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Annovis Bio, Inc. and Encourages Investors to Contact the Firm (Business Wire) -9.15%
08:56PM	SHAREHOLER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Annovis Bio, Inc. of Class Action Lawsuit and Upcoming Deadline - ANVS (PR Newswire)
04:21PM	MONDAY DEADLINE ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Annovis Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (Newsfile)
01:42PM	Insiders Are Snapping Up These 2 Beaten-Down Stocks (TipRanks)
08:15AM	DEADLINE MONDAY NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Annovis Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (ACCESSWIRE)
Oct-14-21 07:10PM	FINAL NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Annovis Bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit ANVS (GlobeNewswire) +12.04%
04:20PM	DEADLINE MONDAY ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Annovis Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm (Newsfile)

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Maccecchini Maria-Luisa	President and CEO	Feb 06	Option Exercise	0.14	52,755	7,386	1,040,489	Feb 08 05:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience